
ASCLERA
ASCLERA.com

ASCLERA®

(polidocanol) Injection

Simple procedure for sustained results

**Uncomplicated spider vein treatment (≤ 1 mm)
patient treated with 0.5% ASCLERA**



Before After

**Uncomplicated reticular vein treatment (1-3 mm)
patient treated with 1% ASCLERA**



Before After

Improvement 18 weeks after last treatment

Visit www.ASCLERA.com for more information THEN ask your Healthcare Provider about ASCLERA to begin your sclerotherapy treatment today.

methapharm
Specialty Pharmaceuticals

ASCLERA is contraindicated for patients with known allergy to polidocanol and patients with acute thromboembolic diseases. In clinical studies, the following adverse reactions were observed after using ASCLERA and were more common with ASCLERA than placebo: injection site hematoma, injection site irritation, injection site discoloration, injection site pain, injection site itching, injection site warmth, neovascularization, injection site clotting. Please consult the package insert for full prescribing information including warnings and precautions, available on request by calling Methapharm Medical Information at 1-866-701-4636, or to view and download at www.ASCLERA.com. To report SUSPECTED ADVERSE REACTIONS, contact Methapharm Medical Information at 1-866-701-4636,or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For all other ASCLERA inquiries please call 1-833-766-8346. References: 1) ASCLERA® Full Prescribing Information. Methapharm, Inc.2) Rabe E, Schliephake D, Otto J, Breu FX, et al. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology 2010;25:124–31.

ASC-US-CC-0525